Hosted by BioInsights · 🇺🇸 US · EN-GB · 62 episodes
Established thought leaders with verified media credentials.
The BioInsights Podcast: discussing the challenges of translating novel biologics from bench to clinic to market.
BioInsights hosts The BioInsights Podcast, a science show with 62 episodes published.
Lauren Coyle, Editor, BioInsights, speaks with Christian Overgaard, Senior Field Application Scientist, Bio‑Rad Laboratories, about the technical and practical evolution of droplet digital PCR (ddPCR) and high‑plex multi
The one‑and‑done model has defined gene therapy for a generation. Chris Hopkins thinks it is time to move on. At ASGCT 2026, Abi Pinchbeck spoke with the Co‑founder and CEO of Glafabra Therapeutics on redoseable cell‑bas
Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Weston Kightlinger, CEO, Ridge Bio, about the challenge of DAR heterogeneity and site specificity in ADC development, Ridge Bio’s ML‑driven en
Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights , speaks with Antoine Yver, Board Chair, Ona Therapeutics, with more than three and a half decades of experience shaping global cancer drug development. In
In this interview, Róisin McGuigan , Editor, Nucleic Acid Insights , and Jesse Erasmus , Director of Virology at HDT Bio, discuss current challenges and opportunities in RNA safety, manufacturing, and targeted delivery,
In this podcast episode, Jokūbas Leikauskas , Editor, BioInsights, speaks to Trevor Hallam , who served as Chief Scientific Officer of Sail Biomedicines until July 2025. The interview, recorded in June 2025, explores adv
Lauren Coyle (Commissioning Editor, Bioconjugation Insights ) speaks to Vincent Rotello (Distinguished Professor of Chemistry, University of Massachusetts Amherst) about the advantages and limitations of different nanoma
Lauren Coyle , Launch Commissioning Editor, Bioconjugation Insights , speaks with Kerstin Hofer , Science and People Lead, Roche, about the evolving application of antibody-oligonucleotide conjugates in neurology. She hi
Jokūbas Leikauskas , Editor, BioInsights, speaks to Rohin Iyer , Senior Director, Global Cell and Gene Therapy Operations, Marken, about addressing the complex logistics of cell and gene therapies through global infrastr
In the last few years, mRNA has moved to the fore in the vaccine and cell and gene therapy fields, and as a result, its successful production for these downstream applications has never been more crucial. In this podcast
Roisin McGuigan , Commissioning Editor, Nucleic Acid Insights , speaks to Stanley Crooke , Chairman, Founder and CEO, n-Lorem, about his long career and pioneering role in the antisense oligonucleotide (ASO) space, how R
Róisin McGuigan , Commissioning Editor, Nucleic Acid Insights , speaks to Ketaki Deshmukh , Senior Scientist, Novo Nordisk, about advanced characterization tools for LNPs, challenges in extrahepatic delivery, scalability
Jokūbas Leikauskas , Editor, Cell & Gene Therapy Insights , speaks with OmniaBio Inc.’s Kenneth Harris , Chief Strategy Officer and Head of AI, Mitchel Sivilotti , President and CEO, and Anthony Rotunno , Senior Vice Pre
Lauren Coyle , Commissioning Editor, Immuno-Oncology Insights , speaks with Banafshé Larijani , Director of the Centre for Therapeutic Innovation, University of Bath, about the development and application of a novel spat
Lauren Coyle , Commissioning Editor, speaks with Dhruv Sareen , Executive Director at Cedars-Sinai Biomanufacturing Center, and Johnathan Rodriguez , Quality Control Manager at Cedars-Sinai Biomanufacturing Center, about
For the first time in history, cell and gene therapy products are reaching the market in waves rather than in one’s and two’s, creating unprecedented challenges for pharma/biotech and healthcare sector stakeholders alike
David McCall , Senior Editor, BioInsights, spoke to Lee Brown , Healthcare Sector Global Team Leader, Third Bridge Group, on Tuesday, February 6, 2024 to gain his insights into the fast-moving market landscape of advance
Translating the therapeutic promise of cell and gene therapies into clinical reality relies on robust potency assays. However, designing assays that accurately reflect the complex mechanisms of these therapies can feel l
Lauren Coyle , Commissioning Editor, Cell & Gene Therapy Insights , talks with Suman Subramanian , Head of Commercial Operations, Catalent Cell and Gene Therapy, to discuss the major achievements in the gene therapy mark
Lauren Coyle , Commissioning Editor, Immuno-Oncology Insights , speaks with André Freitas , Senior Lecturer (University of Manchester) and Research Group Leader (Idiap Research Institute/National Biomarker Centre), about
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch The BioInsights Podcast, visit https://podcast.insights.bio for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent science coverage.
The BioInsights Podcast is hosted by BioInsights. The show is categorised under science (life) and has published 62 episodes.
The BioInsights Podcast has published 62 episodes.
The BioInsights Podcast regularly covers science, life, business. It sits in the science category, with a life focus.
The BioInsights Podcast is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
The BioInsights Podcast hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of The BioInsights Podcast average 24 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates The BioInsights Podcast's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched today.
